Veeva Systems (VEEV)
NYSEHealth CareSoftware - ApplicationSnapshot 2026-09-14
$265.67+1.25%
Close 2026-09-14 · 1-day change
NYSEHealth CareSoftware - ApplicationSnapshot 2026-09-14
Research Workspace
Put VEEV beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 17% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 12%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 51% in its worst 12-month stretch.
View RiskVeeva Systems' AI capabilities must continue to drive growth to justify its valuation. Revenue grew 18% year over year, and the latest quarter beat expectations. It trades at 33× P/E versus a peer median of 20×, indicating the market expects strong growth. If VEEV cuts guidance on the next call, that could negatively impact the stock. Peer multiples imply a price about 18% below where it trades (it looks expensive on this basis). This read is provisional.
Trailing returns as of 2026-09-14. VEEV is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 29 analysts currently covering VEEV (as of Sep 2026).
Based on 20 Wall Street analysts offering 12-month price targets for VEEV in the last 4 months.
Continue this research
Compare VEEV with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| VEEV Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Compare the value case
Put VEEV next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance AI and agentic labor platform development
AI growth potential aligns with product development objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $265.67
The last 12 months of price, then the range of analyst 12-month targets from today’s $265.67.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Advance AI and agentic labor platform development
Falcon AI enhances product development and revenue growth potential.
Advances: Advance AI and agentic labor platform development
AI monetization potential aligns with product development goals.
Advances: Advance AI and agentic labor platform development
Enhances AI platform capabilities, aligning with product development goals.
Advances: Drive revenue growth for fiscal year 2027
Strong revenue growth and operating income support fiscal year 2027 goals.
Advances: Quarterly revenue growth
Quarterly revenue growth exceeded expectations, boosting outlook.
Price target increase suggests positive outlook on revenue growth.
Advances: Non-GAAP EPS guidance for fiscal year 2027
Positive earnings support non-GAAP EPS guidance for fiscal year 2027.
